Arrowhead Pharmaceuticals Inc (ARWR)

1.42
NASDAQ : Health Care
Prev Close 1.42
Day Low/High 0.00 / 0.00
52 Wk Low/High 1.32 / 8.22
Avg Volume 1.50M
Exchange NASDAQ
Shares Outstanding 60.75M
Market Cap 87.48M
EPS -1.60
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Arrowhead Pharmaceuticals Focuses Resources On Subcutaneous And Extra-Hepatic RNAi Therapeutics

Arrowhead Pharmaceuticals Focuses Resources On Subcutaneous And Extra-Hepatic RNAi Therapeutics

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced a strategic redeployment of resources to support the development of RNAi therapeutics that utilize the company's new proprietary subcutaneous (subQ) and...

INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Arrowhead Pharmaceuticals, Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit

INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Arrowhead Pharmaceuticals, Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit

The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Central District of California on behalf...

Arrowhead Pharmaceuticals Announces Closing Of License And Collaboration Agreement With Amgen

Arrowhead Pharmaceuticals Announces Closing Of License And Collaboration Agreement With Amgen

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) is pleased to announce that the license and collaboration agreement between Arrowhead and Amgen covering the novel RNAi ARC-LPA program has closed, following early termination...

IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit Against Arrowhead Pharmaceuticals, Inc. And Encourages Investors With Losses To Contact The Firm

IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit Against Arrowhead Pharmaceuticals, Inc. And Encourages Investors With Losses To Contact The Firm

Khang & Khang LLP (the "Firm") announces a class action lawsuit against Arrowhead Pharmaceuticals, Inc.

IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit Against Arrowhead Pharmaceuticals, Inc. And Encourages Investors With Losses To Contact The Firm

IMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit Against Arrowhead Pharmaceuticals, Inc. And Encourages Investors With Losses To Contact The Firm

Khang & Khang LLP (the "Firm") announces a class action lawsuit against Arrowhead Pharmaceuticals, Inc.

INVESTOR ALERT: Goldberg Law PC Announces Securities Class Action Lawsuit Against Arrowhead Pharmaceuticals, Inc. And Encourages Investors With Losses To Contact The Firm

INVESTOR ALERT: Goldberg Law PC Announces Securities Class Action Lawsuit Against Arrowhead Pharmaceuticals, Inc. And Encourages Investors With Losses To Contact The Firm

Goldberg Law PC, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Arrowhead Pharmaceuticals, Inc.

INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit Against Arrowhead Pharmaceuticals, Inc. And Encourages Investors With Losses To Contact The Firm

INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit Against Arrowhead Pharmaceuticals, Inc. And Encourages Investors With Losses To Contact The Firm

Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against Arrowhead Pharmaceuticals, Inc.

EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against Arrowhead Pharmaceuticals, Inc.

EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against Arrowhead Pharmaceuticals, Inc.

Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals Presents New Data On ARC-F12 And ARC-LPA Using DPCsqTM Subcutaneous RNAi Delivery Vehicle

Arrowhead Pharmaceuticals Presents New Data On ARC-F12 And ARC-LPA Using DPCsqTM Subcutaneous RNAi Delivery Vehicle

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today delivered oral presentations on ARC-LPA, its preclinical development program targeting lipoprotein (a), for the treatment of cardiovascular disease, and ARC-F12, its...

Interesting ARWR Put And Call Options For January 2019

Interesting ARWR Put And Call Options For January 2019

Investors in Arrowhead Pharmaceuticals Inc saw new options become available today, for the January 2019 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 795 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Arrowhead Pharmaceuticals Presents New Data On ARC-AAT

Arrowhead Pharmaceuticals Presents New Data On ARC-AAT

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) delivered a poster presentation with Phase 1 clinical data and an oral presentation with preclinical data on ARC-AAT, its investigational medicine for the treatment of liver...

IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces An Investigation Of Arrowhead Pharmaceuticals, Inc. And Advises Investors With Losses To Contact The Firm

IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces An Investigation Of Arrowhead Pharmaceuticals, Inc. And Advises Investors With Losses To Contact The Firm

Lundin Law PC, a shareholder rights firm, announces that it is investigating claims against Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals Provides Update On Heparc-2004 Study

Arrowhead Pharmaceuticals Provides Update On Heparc-2004 Study

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) is providing an update on its Heparc-2004 clinical study of ARC-520, its therapeutic candidate under clinical investigation for the treatment of chronic hepatitis B virus (HBV)...

Arrowhead Pharmaceuticals To Present At Upcoming Conferences

Arrowhead Pharmaceuticals To Present At Upcoming Conferences

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) will make presentations at the following upcoming events: The 25 th Annual Credit Suisse Healthcare Conference - Scottsdale, AZ, November 6-8, 2016 ...

Relative Strength Alert For Arrowhead Pharmaceuticals

Relative Strength Alert For Arrowhead Pharmaceuticals

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Arrowhead Pharmaceuticals To Present Data On ARC-AAT At The Liver MeetingĀ®

Arrowhead Pharmaceuticals To Present Data On ARC-AAT At The Liver MeetingĀ®

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will make two presentations on ARC-AAT, the company's investigational medicine for the treatment of liver disease associated with alpha-1 antitrypsin...

Arrowhead And Spring Bank Announce Clinical Collaboration For ARC-520 And SB 9200 In Chronic Hepatitis B

Arrowhead And Spring Bank Announce Clinical Collaboration For ARC-520 And SB 9200 In Chronic Hepatitis B

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) and Spring Bank Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals (ARWR) Stock Surges on Amgen Cardiovascular Drug Partnerships

Arrowhead Pharmaceuticals (ARWR) Stock Surges on Amgen Cardiovascular Drug Partnerships

Amgen (AMGN) is partnering with Arrowhead Pharmaceuticals (ARWR) to develop two cardiovascular disease treatments using its RNAi therapy.

First Week of November 18th Options Trading For Arrowhead Pharmaceuticals (ARWR)

First Week of November 18th Options Trading For Arrowhead Pharmaceuticals (ARWR)

Investors in Arrowhead Pharmaceuticals Inc saw new options begin trading this week, for the November 18th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ARWR options chain for the new November 18th contracts and identified one put and one call contract of particular interest.

Arrowhead Pharmaceuticals Initiates Phase 2 Study Of ARC-AAT

Arrowhead Pharmaceuticals Initiates Phase 2 Study Of ARC-AAT

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it initiated a Phase 2 clinical study of ARC-AAT, an investigational RNAi-based medicine for the treatment of liver disease associated with alpha-1...

Arrowhead Pharmaceuticals To Present At Upcoming September Conferences

Arrowhead Pharmaceuticals To Present At Upcoming September Conferences

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the company will make presentations at the following upcoming events.

Notable Thursday Option Activity: ARWR, ROST, OUTR

Notable Thursday Option Activity: ARWR, ROST, OUTR

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Arrowhead Pharmaceuticals Inc , where a total of 3,324 contracts have traded so far, representing approximately 332,400 underlying shares. That amounts to about 61.7% of ARWR's average daily trading volume over the past month of 538,710 shares.

Arrowhead Pharmaceuticals Closes $45 Million Private Offering

Arrowhead Pharmaceuticals Closes $45 Million Private Offering

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it closed a previously announced private offering with a select group of investors including Orbimed, RA Capital Management, Perceptive Advisors, RTW...